

Acknowledgments

We are grateful to the staff and residents of the SNF described in this study. We thank the Washington State Department of Health Office of Communicable Disease Epidemiology Staff who worked to collect specimens for WGS and provided data for the project. We also thank the Washington State Department of Health Public Health Laboratories COVID-19 Team who generated the SARS-CoV-2 genomic data and shared this data to GISAID.

This work was funded by the Centers for Disease Control and Prevention and Public Health Seattle and King County.

About the Author

Dr. Lewis is a board-certified physician in internal medicine, infectious disease, and preventive medicine. He is currently the health officer for the Snohomish County Health District; prior to this position and during the initial composition of this article he was a medical epidemiologist at Public Health Seattle & King County helping to oversee the response to the SARS-CoV-2 pandemic in healthcare settings.

References

1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. *N Engl J Med*. 2020;383:2603–15. <https://doi.org/10.1056/NEJMoa2034577>
2. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med*. 2021;384:403–16. <https://doi.org/10.1056/NEJMoa2035389>
3. Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant – National Healthcare Safety Network, March 1–August 1, 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70:1163–6. <https://doi.org/10.15585/mmwr.mm7034e3>
4. Mazagatos C, Monge S, Olmedo C, Vega L, Gallego P, Martín-Merino E, et al.; Working Group for the surveillance and control of COVID-19 in Spain; Working group for the surveillance and control of COVID-19 in Spain. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021. *Euro Surveill*. 2021;26:2100452. <https://doi.org/10.2807/1560-7917.ES.2021.26.24.2100452>
5. Lefèvre B, Tondeur L, Madec Y, Grant R, Lina B, van der Werf S, et al. Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France. *Lancet Healthy Longev*. 2021;2:e685–7. [https://doi.org/10.1016/S2666-7568\(21\)00230-0](https://doi.org/10.1016/S2666-7568(21)00230-0)
6. Cavanaugh AM, Fortier S, Lewis P, Arora V, Johnson M, George K, et al. COVID-19 outbreak associated with a SARS-CoV-2 R.1 lineage variant in a skilled nursing facility after vaccination program – Kentucky, March 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70:639–43. <https://doi.org/10.15585/mmwr.mm7017e2>
7. Williams C, Al-Bargash D, Macalintal C, Stuart R, Seth A, Latham J, et al. Coronavirus disease 2019 (COVID-19) outbreak associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) P.1 lineage in a long-term care home after implementation of a vaccination program – Ontario, Canada, April–May 2021. *Clin Infect Dis*. 2022;74:1085–8. <https://doi.org/10.1093/cid/ciab617>

Address for correspondence: James Lewis, 3020 Rucker Ave, Ste 206, Everett, WA 98201, USA; email: jlewis@snohd.org; Katherine Fleming-Dutra, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop H24-6, Atlanta, GA 30329-4027, USA; email: ftu2@cdc.gov

Reinfections with Different SARS-CoV-2 Omicron Subvariants, France

Nhu Ngoc Nguyen, Linda Houhamdi, Léa Delorme, Philippe Colson, Philippe Gautret

Author affiliations: Aix Marseille University, Marseille, France; Institut Hospitalo-Universitaire Méditerranée Infection, Marseille

DOI: <https://doi.org/10.3201/eid2811.221109>

We describe 188 patients in France who were successfully infected with different SARS-CoV-2 Omicron subvariants, including BA.1, BA.2, and BA.5. Time between 2 infections was ≤ 90 days for 50 (26.6%) patients and < 60 days for 28 (14.9%) patients. This finding suggests that definitions for SARS-CoV-2 reinfection require revision.

In Belgium, 96 cases of early SARS-CoV-2 reinfection were reported during December 1, 2021–March 10, 2022; the cases had a median of 47 days (range 17–65 days) between 2 positive samples (1). Five of those cases indicated primary infections with Omicron subvariant BA.1, followed by Omicron BA.2 reinfections. In addition, we previously reported that the reinfection risk with Omicron was 6-fold higher than with other SARS-CoV-2 variants (2). In this study, we describe cases of COVID-19 reinfection with different Omicron subvari-

ants after a primary infection with Omicron subvariants BA.1 or BA.2 in Marseilles, France. We performed real-time reverse transcription PCR and next-generation genomic sequencing of nasopharyngeal swab samples to identify subvariants as previously described (3). We retrospectively retrieved patient age and gender information from electronic medical files and anonymized data before analysis. We identified reinfected patients by using a computerized alert system that focused on samples with primary Omicron BA.1 or BA.2 subvariant infections followed by reinfection with any Omicron subvariant. This study was approved by the ethics committee of the University Hospital Institute Méditerranée Infection (approval no. 2022-029). Access to patient biologic and registry data in the hospital information system was approved by the data protection committee of Assistance Publique-Hôpitaux de Marseille and recorded in the European General Data Protection Regulation registry (no. RGPD/APHM 2019-73).

We identified 188 (0.7%) cases of reinfection out of 27,972 patient samples that tested positive for the SARS-CoV-2 Omicron variant during November 28, 2021–July 22, 2022. Of those 188 patients, 181 were first infected with the Omicron BA.1 subvariant and were reinfected as follows: 82 patients with Omicron BA.2, 14 patients with Omicron BA.4, 84 patients with Omicron BA.5, and 1 patient with a BA.1 and BA.2 recombinant subvariant (XAC recombinant lineage) (Appendix Figure, <https://wwwnc.cdc.gov/EID/article/28/11/22-1109-App1.pdf>). Three of the 181 patients infected with Omicron BA.1 were reinfected

2 times; for the first reinfection, they were infected with Omicron BA.2 and, for the second reinfection, they were infected with Omicron BA.5. In addition, 7 patients were first infected with the Omicron BA.2 subvariant, after which 1 patient was reinfected with the Omicron BA.4 subvariant, and 6 patients were reinfected with the Omicron BA.5 subvariant.

Patients were 1–83 (median 32) years of age at the time of their second infection, and 131 (69.7%) were women. The median time between the primary and secondary infections was 146 days (range 7–214 days); median time between infection with Omicron BA.1 and reinfection with BA.2 was 84 days and for a primary infection with Omicron BA.1 and reinfection with BA.5 was 171 days (Appendix Figure). Among the 188 patients infected first with Omicron BA.1 or BA.2, the time between the primary and secondary infections was 1–29 days in 6 (3.2%) cases, 30–44 days in 4 (2.1%) cases, 45–59 days in 18 (9.6%) cases, 60–74 days in 10 (5.3%) cases, 75–89 days in 11 (5.8%) cases, and ≥ 90 days in 139 (73.9%) cases. In 50/188 (26.6%) patients, time between the 2 infections was ≤ 90 days and, in 28/188 (14.9%) patients, the time was < 60 days between the 2 infections.

Our findings indicate that the time between confirmed primary infections and reinfections with different Omicron subvariants is frequently shorter than the 90-day definition of reinfections used by the US Centers for Disease Control and Prevention (4). Furthermore, the time can be shorter than the 60-day definition of reinfections used by the European Centre for Disease




Figure. Number of patients with infections from different SARS-CoV-2 Omicron subvariants, France, November 28, 2021–July 22, 2022. Overall dynamics of infections with Omicron subvariants BA.1, BA.2, BA.4, and BA.5 are shown for cases diagnosed at the Institut Méditerranée Infection, Marseille, France. We performed real-time reverse transcription PCR and next-generation genomic sequencing of nasopharyngeal swab samples to identify Omicron subvariants BA.1, BA.2, BA.4, and BA.5. A total of 27,972 patient samples tested positive for Omicron subvariants.

Prevention and Control (5). Similar to our findings, a study from Denmark reported 47 Omicron BA.2 reinfections that occurred 20–60 days after a primary BA.1 infection (M. Stegger et al., unpub. data, <https://www.medrxiv.org/content/10.1101/2022.02.19.22271112v1>).

The first limitation of our study is that the number of cases was small. Second, we cannot exclude that some cases might have been concurrent infections with different subvariants, notably in the 3 cases that had a 7-day interval between the detection of 2 subvariants. In Marseille, the short time between emergence of different Omicron subvariants might have favored co-infections with different subvariants circulating within the population (Figure). Co-infections can be missed if the quantitative PCR has inadequate sensitivity, and whole-genome sequencing might fail to detect a variant with low prevalence in a patient. Finally, because most reinfection cases were identified from samples transferred to our laboratory by external entities, we were unable to describe COVID-19 vaccination and clinical status of the patients. Nonetheless, our results suggest that the currently used definitions for SARS-CoV-2 reinfection require revision with regard to the duration between primary and secondary infections.

This work was supported by the “Investments for the Future” program managed by the National Agency for Research (ANR) (Méditerranée-Infection 10-IAHU-03), Région Provence Alpes Côte d’Azur, European funding agency FEDER PRIMMI (Fonds Européen de Développement Régional-Plateformes de Recherche et d’Innovation Mutualisées Méditerranée Infection) (FEDER PA 0000320 PRIMMI), Ministry of Higher Education, Research and Innovation (Ministère de l’Enseignement supérieur, de la Recherche et de l’Innovation), and Ministry of Solidarity and Health (Ministère des Solidarités et de la Santé), France.

About the Author

Dr. Nguyen is a medical doctor and PhD student at the Aix Marseille University and Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France. Her research interests focus on long COVID and SARS-CoV-2 reinfections.

References

1. Nevejan L, Cuypers L, Laenen L, Van Loo L, Vermeulen F, Wollants E, et al. Early SARS-CoV-2 reinfections within 60 days and implications for retesting policies. *Emerg Infect Dis*. 2022;28:1729–31. <https://doi.org/10.3201/eid2808.220617>
2. Nguyen NN, Houhamdi L, Hoang VT, Stoupan D, Fournier PE, Raoult D, et al. High rate of reinfection with

the SARS-CoV-2 Omicron variant. *J Infect*. 2022;85:174–211. <https://doi.org/10.1016/j.jinf.2022.04.034>

3. Colson P, Fournier PE, Chaudet H, Delerce J, Giraud-Gatineau A, Houhamdi L, et al. Analysis of SARS-CoV-2 variants from 24,181 patients exemplifies the role of globalization and zoonosis in pandemics. *Front Microbiol*. 2022;12:786233. <https://doi.org/10.3389/fmicb.2021.786233>
4. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) 2021 case definition [cited 2022 Sep 8]. <https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021>
5. European Centre for Disease Prevention and Control. Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA [cited 2022 Sep 8]. <https://www.ecdc.europa.eu/en/publications-data/reinfection-sars-cov-2-implementation-surveillance-case-definition-within-eueea>

Address for correspondence: Philippe Gautret, VITROME, Institut Hospitalo-Universitaire Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13385 Marseille CEDEX 05, France; email: philippe.gautret@club-internet.fr


Human Parainfluenza Virus in Homeless Shelters before and during the COVID-19 Pandemic, Washington, USA

Eric J. Chow, Amanda M. Casto, Reigran Sampoleo, Margaret G. Mills, Peter D. Han, Hong Xie, Brian Pfau, Tien V. Nguyen, Jaydee Sereewit, Julia H. Rogers, Sarah N. Cox, Melissa A. Rolfes, Constance Ogokeh, Emily Mosites, Timothy M. Uyeki, Alexander L. Greninger, James P. Hughes, M. Mia Shim, Nancy Sugg, Jeffrey S. Duchin, Lea M. Starita, Janet A. Englund, Pavitra Roychoudhury, Helen Y. Chu

Author affiliations: University of Washington, Seattle, Washington, USA (E.J. Chow, A.M. Casto, R. Sampoleo, M.G. Mills, P.D. Han, H. Xie, B. Pfau, T.V. Nguyen, J. Sereewit, J.H. Rogers, S.N. Cox, A.L. Greninger, J.P. Hughes, M.M. Shim, N. Sugg, J.S. Duchin, L.M. Starita, P. Roychoudhury, H.Y. Chu); Fred Hutchinson Cancer Research Center, Seattle (A.M. Casto, A.L. Greninger, J.P. Hughes, P. Roychoudhury); Brotman Baty Institute for

Reinfections with Different SARS-CoV-2 Omicron Subvariants, France

Appendix



Appendix Figure. Number of days between primary infection and reinfections with different SARS-CoV-2 Omicron subvariants, France. Box plots indicate the number of days between 2 episodes of Omicron SARS-CoV-2 infections in 188 patients from Marseilles, France. The x axis indicates the primary infection with either Omicron subvariant BA.1 or BA.2 followed by reinfection with a different Omicron subvariant. The vertical line inside the box represents the median, and the mean is marked with an X. The ends of the boxes are the lower and upper quartiles that represent observations outside the 25–75 percentile range. The error bars show the minimum and maximum values. Data falling outside the upper and lower quartile range are plotted as outliers.